Horizon Pharma Inc. (HZNP)
Россия
  • Россия
  • Украина

Horizon Pharma Inc. (HZNP)

Contact Details

520 Lake Cook Rd Ste 520, Deerfield, Illinois, USA 60015-5633
(224) 383-3000
520 Lake Cook Rd Ste 520, Deerfield, Illinois, USA 60015-5633

General Information

Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients` lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company`s U.S. marketed products are ACTIMMUNE? (interferon gamma-1b), DUEXIS? (ibuprofen/famotidine), PENNSAID? (diclofenac sodium topical solution) 2% w/w, RAYOS? (prednisone) delayed-release tablets and VIMOVO? (naproxen/esomeprazole magnesium). Horizon`s global headquarters are in Dublin, Ireland.

Contact Information

Phone(224) 383-3000
Website 1http://www.horizonpharma.com
LinkedInLinkedIn
Thomson Reuters PermID5037276891

Executives

NamePositionTotal Annual CompensationYearPercent Change in Compensation
CEO, Chairman of the Board and President$7,763,5282014309.6%
Executive VP and CFO$3,043,4562014
Executive VP and Other Executive Officer$5,639,9232014
Executive VP and Other Executive Officer$2,829,4622014
Divisional Executive VP$2,961,0892014

Corporate Data

Industries

  • Pharmaceutical Preparation Manufacturing

SIC Industries

  • Pharmaceutical Preparations

Company Size

Sales Volume$757 million
Employees750

Ownership

Ticker SymbolHZNP
ExchangeNASDAQ Global Market
Year Founded2014

Stocks

Previous Close18.22
Open14.90
Bid14.48 x 2,500
Ask14.50 x 300
Day`s Range14.23 - 15.35
52-Week Range13.12 - 38.45
Average Volume (1M)3,994,722
Forward P/E7.5x
Trailing P/E12.05x
Beta1.86x
Market Cap.$3,006.51 Million
Last Dividend Amount0
1y Target Price Est.41.83

Pre-IPO

Form-D Filings

Filing DateFiling TypeTotal Offering AmountTotal Amount RaisedTotal Remaining For Sale
March 07, 2012New$32,772$32,772$0

Financials

Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue244,538226,544172,821113,141
Cost of Revenue67,57361,25061,82628,853
Gross Profit176,965165,294110,99584,288
Research Development13,68913,0738,9226,181
Selling General and Administrative125,227106,489135,24673,343
Depreciation and Amortization----
Other Operating Expenses----
Total Operating Expenses206,489180,812205,994108,377
Other Income/Expenses Net(0.1)---
Earnings Before Interest and Taxes38,04945,732(33,173)4,764
Interest Expense20,12020,30019,44810,032
Income Before Tax(11,462)25,256(128,866)(17,640)
Income Tax Expense(35,456)21,979(160,680)1,913
Minority Interest----
Net Income from Continuing Ops23,9943,27731,814(19,553)
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income23,9943,27731,814(19,553)
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares23,9943,27731,814(19,553)